There’s No Need To Panic Or Freeze When It Comes To Crinetics Pharmaceuticals Inc (NASDAQ: CRNX)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Crinetics Pharmaceuticals Inc is $3.58B. A total of 0.86 million shares were traded on the day, compared to an average of 765.61K shares.

In the most recent transaction, Okey Stephanie sold 17,500 shares of CRNX for 46.38 per share on Mar 28 ’24. After the transaction, the Director now owns 6,000 company shares. In a previous transaction on Mar 22 ’24, Knight Jeff E. sold 32,359 shares at 44.31 per share. CRNX shares that Chief Operating Officer owns now total 52,580.

Among the insiders who sold shares, Fust Matthew K disposed of 60,000 shares on Mar 20 ’24 at a per-share price of $44.14. This resulted in the Director holding 18,536 shares of CRNX after the transaction. In another insider transaction, Pizzuti Dana sold 15,089 shares at $44.06 per share on Mar 20 ’24. Company shares held by the Chief Med and Dev Officer now total 27,786.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, CRNX has a high of $47.62 and a low of $15.50.

As of this writing, CRNX has an earnings estimate of -$0.81 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.68 per share and a lower estimate of -$0.94. The company reported an EPS of -$1.01 in the last quarter, which was -17.40% lower than expectations of -$0.86.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CRNX’s latest balance sheet shows that the firm has $333.71M in Cash & Short Term Investments as of fiscal 2021. There were $3.07M in debt and $15.99M in liabilities at the time. Its Book Value Per Share was $7.91, while its Total Shareholder’s Equity was $331.94M.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRNX is Buy with a score of 4.85.

Most Popular

Related Posts